Kelun-Biotech Revenue Surges 112% on ADC Expansion and Global Trials
Event summary
- Kelun-Biotech reported RMB 978 million in revenue for H1 2026, with pharmaceutical sales up 112% YoY to RMB 657 million.
- Sac-TMT (佳泰莱®) gained marketing approval for 2L+ HR+/HER2- breast cancer and saw new indication applications accepted for 1L TNBC and 1L PD-L1-positive NSCLC.
- Global Phase 3 TroFuse-005 trial for sac-TMT in endometrial cancer met primary endpoints, marking a first for ADC therapy in this setting.
- Company raised HK$2.723 billion in H-share placement and removed
The big picture
Kelun-Biotech's strong financial performance reflects the growing clinical and commercial validation of its ADC platform, particularly sac-TMT. The company's strategic focus on combination therapies and earlier-line treatment settings aligns with broader industry trends toward more targeted and effective cancer treatments. Its ability to secure global partnerships and regulatory approvals positions it as a key player in the evolving ADC therapy landscape.
What we're watching
- Global Expansion
- The pace at which Kelun-Biotech can translate its Chinese success into global markets through strategic partnerships and independent market entry.
- Pipeline Diversification
- Whether the company's expansion into autoimmune and metabolic diseases can deliver meaningful clinical and commercial results beyond its core oncology focus.
- Commercial Execution
- How effectively Kelun-Biotech can scale its commercial operations to support its growing product portfolio and maintain its 112% YoY revenue growth trajectory.
Related topics